東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Drug Safety and Pharmacovigilance." ]

切換: 標籤 | MARC模式 | ISBD

The challenge of CMC regulatory comp...

Geigert, John.

FindBook

Google Book

Amazon

博客來

The challenge of CMC regulatory compliance for biopharmaceuticals

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The challenge of CMC regulatory compliance for biopharmaceuticals/ by John Geigert.
其他題名:	Challenge of chemistry, manufacturing, and control regulatory compliance for biopharmaceuticals
作者:	Geigert, John.
出版者:	Cham :Springer International Publishing : : 2019.,
面頁冊數:	xxviii, 426 p. :ill., digital ;24 cm.
內容註:	Complexity of Biologics CMC Regulation -- Biopharmaceutics are Not Chemical Drugs -- An Effective CMC Strategy is Possible -- Challenge of Adventitious Agent Control -- Biopharmaceutical Source Materials -- Manufacturing of Biopharmaceutical APIs -- Manufacturing of the Drug Product -- Complex Process-Related Impurity Profiles -- Product Characterization is a Journey -- Priceless Potency (Therapeutic Activity) -- Quality Attributes of a Biopharmaceutical -- Designing the Stability Program -- The Art of Setting Specifications -- Demonstrating Product Comparability After Process Changes -- Invaluable CMC-Focused Meetings with Regulatory Authorities.
Contained By:	Springer eBooks
標題:	Pharmaceutical biotechnology industry - Law and legislation. -
電子資源:	https://doi.org/10.1007/978-3-030-13754-0
ISBN:	9783030137540

The challenge of CMC regulatory compliance for biopharmaceuticals
Geigert, John.

The challenge of CMC regulatory compliance for biopharmaceuticals[electronic resource] /Challenge of chemistry, manufacturing, and control regulatory compliance for biopharmaceuticalsby John Geigert. - 3rd ed. - Cham :Springer International Publishing :2019. - xxviii, 426 p. :ill., digital ;24 cm.

Complexity of Biologics CMC Regulation -- Biopharmaceutics are Not Chemical Drugs -- An Effective CMC Strategy is Possible -- Challenge of Adventitious Agent Control -- Biopharmaceutical Source Materials -- Manufacturing of Biopharmaceutical APIs -- Manufacturing of the Drug Product -- Complex Process-Related Impurity Profiles -- Product Characterization is a Journey -- Priceless Potency (Therapeutic Activity) -- Quality Attributes of a Biopharmaceutical -- Designing the Stability Program -- The Art of Setting Specifications -- Demonstrating Product Comparability After Process Changes -- Invaluable CMC-Focused Meetings with Regulatory Authorities.

This book since first published in 2004 has been a major resource providing insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation) The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

ISBN: 9783030137540

Standard No.: 10.1007/978-3-030-13754-0doiSubjects--Topical Terms:

3410207
Pharmaceutical biotechnology industry
--Law and legislation.

LC Class. No.: RS380 / .G454 2019

Dewey Class. No.: 615.19

The challenge of CMC regulatory compliance for biopharmaceuticals
LDR:03060nmm a2200349 a 4500 001 2191118
003 DE-He213
005 20191015165356.0
006 m d
007 cr nn 008maaau
008 200504s2019 gw s 0 eng d
020 $a 9783030137540 $q (electronic bk.)
020 $a 9783030137533 $q (paper)
024 7 $a 10.1007/978-3-030-13754-0 $2 doi
035 $a 978-3-030-13754-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RS380 $b .G454 2019
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615.19 $2 23
090 $a RS380 $b .G312 2019
100 1 $a Geigert, John. $3 3410206
245 1 4 $a The challenge of CMC regulatory compliance for biopharmaceuticals $h [electronic resource] / $c by John Geigert.
246 3 $a Challenge of chemistry, manufacturing, and control regulatory compliance for biopharmaceuticals
250 $a 3rd ed.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a xxviii, 426 p. : $b ill., digital ; $c 24 cm.
505 0 $a Complexity of Biologics CMC Regulation -- Biopharmaceutics are Not Chemical Drugs -- An Effective CMC Strategy is Possible -- Challenge of Adventitious Agent Control -- Biopharmaceutical Source Materials -- Manufacturing of Biopharmaceutical APIs -- Manufacturing of the Drug Product -- Complex Process-Related Impurity Profiles -- Product Characterization is a Journey -- Priceless Potency (Therapeutic Activity) -- Quality Attributes of a Biopharmaceutical -- Designing the Stability Program -- The Art of Setting Specifications -- Demonstrating Product Comparability After Process Changes -- Invaluable CMC-Focused Meetings with Regulatory Authorities.
520 $a This book since first published in 2004 has been a major resource providing insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation) The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.
650 0 $a Pharmaceutical biotechnology industry $x Law and legislation. $3 3410207
650 0 $a Pharmaceutical biotechnology $x Quality control. $3 916642
650 1 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-3-030-13754-0
950 $a Biomedical and Life Sciences (Springer-11642)